Eyenovia (NASDAQ:EYEN) Shares Up 3.1%

Eyenovia, Inc. (NASDAQ:EYENGet Free Report) was up 3.1% during trading on Friday . The stock traded as high as $1.90 and last traded at $1.83. Approximately 459,388 shares changed hands during mid-day trading, an increase of 11% from the average daily volume of 414,832 shares. The stock had previously closed at $1.78.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on EYEN. Brookline Capital Management initiated coverage on shares of Eyenovia in a report on Tuesday, October 17th. They set a “buy” rating and a $8.00 price target on the stock. William Blair reiterated an “outperform” rating on shares of Eyenovia in a research note on Wednesday, November 1st. Finally, HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Eyenovia in a research note on Tuesday, November 14th.

Read Our Latest Analysis on EYEN

Eyenovia Price Performance

The business’s 50 day moving average price is $1.77 and its 200 day moving average price is $1.68. The stock has a market capitalization of $80.74 million, a P/E ratio of -2.77 and a beta of 1.74. The company has a debt-to-equity ratio of 0.70, a current ratio of 4.05 and a quick ratio of 4.04.

Eyenovia (NASDAQ:EYENGet Free Report) last released its earnings results on Monday, November 13th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.01. Sell-side analysts forecast that Eyenovia, Inc. will post -0.67 EPS for the current year.

Hedge Funds Weigh In On Eyenovia

Hedge funds have recently modified their holdings of the stock. Financial Management Network Inc. bought a new stake in Eyenovia in the third quarter worth $128,000. American International Group Inc. bought a new stake in Eyenovia in the second quarter worth $32,000. Meitav Investment House Ltd. bought a new stake in Eyenovia in the second quarter worth $1,104,000. Oak Family Advisors LLC increased its position in Eyenovia by 36.9% in the second quarter. Oak Family Advisors LLC now owns 61,146 shares of the company’s stock worth $145,000 after purchasing an additional 16,485 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in Eyenovia in the second quarter worth $65,000. Hedge funds and other institutional investors own 16.66% of the company’s stock.

About Eyenovia

(Get Free Report)

Eyenovia, Inc, a pre-commercial ophthalmic company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. It focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system.

Featured Stories

Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.